[HTML][HTML] The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report
J Zang, H Horinouchi, J Hanaoka, K Funai… - Journal of Thoracic …, 2021 - ncbi.nlm.nih.gov
Studies have revealed that the epidermal growth factor receptor (EGFR) mutation is one of
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …
the driving mutations in non-small cell lung cancer (NSCLC)(1, 2). Thus, EGFR tyrosine …
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation
K Takamochi, K Suzuki, H Sugimura, K Funai, H Mori… - Lung Cancer, 2007 - Elsevier
Gefitinib is the first approved epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
inhibitor (TKI) for the treatment of patients with advanced non-small cell lung cancer …
[HTML][HTML] Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
Y Zheng, M Zhou, S Arulananda, SW Um… - Journal of thoracic …, 2020 - ncbi.nlm.nih.gov
First and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) have been widely employed as first line therapy for advanced non-small cell …
inhibitors (TKIs) have been widely employed as first line therapy for advanced non-small cell …
Salvage surgery for advanced non–small cell lung cancer after response to gefitinib
T Hishida, K Nagai, T Mitsudomi, K Yokoi… - The Journal of Thoracic …, 2010 - jtcvs.org
Salvage surgery for advanced non–small cell lung cancer after response to gefitinib - The
Journal of Thoracic and Cardiovascular Surgery Skip to Main Content Advertisement The …
Journal of Thoracic and Cardiovascular Surgery Skip to Main Content Advertisement The …
[引用][C] Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment
H Shen, X Zhong, X Ge, J Huang… - The Clinical Respiratory …, 2010 - Wiley Online Library
Gefitinib (AstraZeneca, Newark, DE, USA) is the first targeted drug to be approved for
advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. It has …
advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. It has …
[HTML][HTML] Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review
Y Yamamoto, K Kodama, T Maniwa… - Journal of Cardiothoracic …, 2017 - Springer
Background The usefulness of residual tumor resection after epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment remains unclear. We describe two …
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment remains unclear. We describe two …
Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases
EV Levchenko, VM Moiseyenko, DE Matsko… - Oncology Research …, 2009 - karger.com
Background: Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal
growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib …
growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib …
[PDF][PDF] Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations
A Morabito, R Costanzo, AM Rachiglio, R Pasquale… - J Thorac …, 2013 - academia.edu
Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) can be
considered the standard firstline therapy of patients with advanced non–small-cell lung …
considered the standard firstline therapy of patients with advanced non–small-cell lung …
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor
R Ko, H Kenmotsu, Y Hisamatsu, H Akamatsu… - International journal of …, 2015 - Springer
Background It is unclear whether there is a difference in the effect of gefitinib treatment
between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and …
between patients with postoperative recurrent non-small cell lung cancer (NSCLC) and …
[HTML][HTML] Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report
W Du, Y Zhao, Y Xuan, Y Qin, R Xu… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
Gefitinib, the first-generation epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non …
(EGFR-TKI), has become the standard of care for the first-line of therapy for advanced non …